Carregant...

Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

PURPOSE: To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma. PATIENTS AND METHODS: Thirty-three patients were treated with EMD 273063, a humanized anti-GD2 monoclonal antibody (mAb) link...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: King, David M., Albertini, Mark R., Schalch, Heidi, Hank, Jacquelyn A., Gan, Jacek, Surfus, Jean, Mahvi, David, Schiller, Joan H., Warner, Thomas, Kim, KyungMann, Eickhoff, Jens, Kendra, Kari, Reisfeld, Ralph, Gillies, Stephen D., Sondel, Paul
Format: Artigo
Idioma:Inglês
Publicat: 2004
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2367368/
https://ncbi.nlm.nih.gov/pubmed/15483010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2004.11.035
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!